Welcome to NeurologyLive's Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive's widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.
 

1: Biogen Files Aducanumab BLA for Alzheimer Disease

Biogen’s biologics license application for aducanumab is supported by the phase 3 EMERGE and ENGAGE trials. The company has also requested a priority review designation.
 
 

2: Insights: Practical Advice on the Management of PD OFF Episodes

Concluding his discussion on Parkinson disease OFF episodes management, Peter LeWitt, MD, shares practical advice regarding the use of on-demand therapy.
 
 

3: COVID-19 Linked to Potential New Neurologic Symptoms in Children

One of the first case-series studies that analyzed children with COVID-19 suggests that SARS-CoV-2 should be considered for differential diagnosis in children presenting with new neurologic symptoms and splenium signal changes on MRI.
 
 

4: Neurology Groups Come Together to Support Continued Telemedicine Service, Payment Parity

Despite the ongoing public health emergency, many of the telehealth policies established by the CARES Act waiver are expiring.
 

5: News Network: Brivaracetam in Children With PGS or Mixed Seizure Types

Anup Patel, MD, offers considerations for recent data with adjunctive brivaracetam in pediatric patients with primary generalized seizures or mixed seizure types.